资讯

Cleveland APL hopes to Clear the Shelters with free and reduced-price pet adoptions this August
The Cleveland APL is offering waived and reduced adoption fees throughout August as part of the nationwide Clear the Shelters ...
Johns Hopkins University Applied Physics Laboratory21 小时
In Memoriam: Johns Hopkins APL Senior Fellow Phil E. DePoy
APL mourns the passing of former Senior Fellow Phil E. DePoy, who died July 12 at the age of 89. In 2014, DePoy was named one ...
Taiwan News1 天
India Ortho-Xylene Market to Reach USD 266.5 Million by 2030, Growing at a CAGR of 5.72%
India Ortho-Xylene Market Size Expands at 5.72% CAGR to Reach USD 266.5 Million by 2030 India Ortho-Xylene Market is flourishing because of a rising demand for phthalic anhydride and for plasticizers.
These ‘Healthier’ Lunch Kits Contain Lead and Phthalates, Consumer Reports Finds
As lab results reveal serious safety concerns behind bright packaging and bold claims, experts warn that this convenience ...
Lunchly Not a Healthier Option Than Lunchables
CR looked at the nutritional content of Lunchly kits and tested them for lead, other heavy metals, and plasticizers. Are they ...
Butyraldehyde Market worth $6.96 billion by 2030 - Exclusive Report by MarketsandMarkets™
The report "Butyraldehyde Market by Product Type (N-Butyraldehyde, Isobutyraldehyde), Application (Chemical Intermediates, ...
亚虹医药：APL - 1401 Ⅰb 期试验获积极初步结果
【亚虹医药APL - 1401结肠炎Ⅰb期临床试验获积极初步结果】7月31日，亚虹医药(688176.SH)公告透露，其开展的APL - 1401用于治疗中重度活动性溃疡性结肠炎的Ⅰb期临床试验有积极初步结果。APL - 1401是强效、选择性多巴胺β - 羟化酶抑制剂，能让肠道免疫稳态恢复正常。公司计划在更大规模患者中评估其12周治疗周期疗效。
【亚虹医药：APL-1401用于治疗中重
【亚虹医药：APL-1401用于治疗中重度活动性溃疡性结肠炎的Ⅰb期临床试验获积极初步结果】亚虹医药(688176)7月31日晚间公告，公司开展的APL-1401用于治疗中重度活动性溃疡性结肠炎的Ⅰb期临床试验获得了积极的初步结果。基于本研究取得的积极结果，公司计划在更大规模的中重度活动性溃疡性结肠炎（UC）患者群体中，进一步评估该潜在first-in-class疗法在12周治疗周期中的疗效，为后 ...
腾讯网2 天
亚虹医药：APL-1401 Ib期临床试验获得积极初步结果
亚虹医药公告，公司开展的APL-1401用于治疗中重度活动性溃疡性结肠炎的Ⅰb期临床试验获得了积极的初步结果。APL-1401是一种强效、选择性的多巴胺β-羟化酶（DBH）抑制剂，通过抑制DBH，从而阻断了多巴胺（DA）合成去甲肾上腺素（NE）唯一的催化酶，导致DA升高、NE降低，使肠道免疫稳态恢复正常。目前溃疡性结肠炎（UC）尚无 ...
亚虹医药：APL-1401用于治疗中重度活动性溃疡性结肠炎的Ⅰb期临床 ...
人民财讯7月31日电，亚虹医药 (688176)7月31日晚间公告，公司开展的APL-1401用于治疗中重度活动性溃疡性结肠炎的Ⅰb期临床试验获得了积极的初步结果。基于本研究取得的积极结果，公司计划在更大规模的中重度活动性溃疡性结肠炎（UC）患者群体中，进一步评估该潜在first-in-class疗法在12周治疗周期中的疗效，为后续临床研究提供更全面的支持性依据，以期未来为患者提供新的治疗选择。
腾讯网2 天
亚虹医药：APL-1401Ⅰb期临床试验获积极初步结果
每经AI快讯，7月31日，亚虹医药(688176.SH)公告称，公司开展的APL-1401用于治疗中重度活动性溃疡性结肠炎的Ⅰb期临床试验获得了积极的初步结果。APL-1401是一种强效、选择性的多巴胺β-羟化酶（DBH）抑制剂，通过抑制DBH，阻断 ...
What’s really inside your mattress?
You probably spend more time with your mattress than any other piece of furniture. But you also probably don’t know exactly ...